Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciprofloxacin for Inhalation
- Development stage
- Phase 3
- Lead developer
- Paradigm Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Ciprofloxacin for Inhalation (CFI) is an investigational antibiotic formulation developed by Aradigm Corporation for the treatment of chronic lung infections, specifically those caused by *Pseudomonas aeruginosa* in patients with non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis. The most advanced version, ARD-3150 (Linhaliq), is a dual-release formulation that combines liposome-encapsulated ciprofloxacin for sustained release with unencapsulated ciprofloxacin for an immediate antibacterial effect. This delivery method, utilizing the AERx pulmonary delivery system, aims to achieve high concentrations of the drug directly at the site of infection while minimizing systemic exposure and associated side effects. Ciprofloxacin is a fluoroquinolone that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription.
- Brand names
- LinhaliqApulmiq
- Other names
- Inhaled CiprofloxacinLiposomal Ciprofloxacin for Inhalation
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on Ciprofloxacin for Inhalation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ciprofloxacin for Inhalation.